Literature DB >> 15090961

Response to exogenous surfactant is different during open lung and conventional ventilation.

Anton H van Kaam1, Jack J Haitsma, Willem A Dik, Birgitta A Naber, Elise H Alblas, Anne De Jaegere, Joke H Kok, Burkhard Lachmann.   

Abstract

OBJECTIVE: Previous studies have shown that the efficacy of exogenous surfactant is dose-dependent during conventional positive pressure ventilation (PPVCON). The present study aimed to determine whether this dose-dependent relationship is also present during open lung (OLC) ventilation. We also explored the effect of exogenous surfactant on the ventilation pressures applied during ventilation.
DESIGN: Animal study.
SETTING: University-affiliated research laboratory.
SUBJECTS: Seventy-two newborn piglets.
INTERVENTIONS: After repeated whole lung lavage, animals were randomly allocated to two surfactant groups receiving either 100 mg/kg surfactant (S100) or 25 mg/kg surfactant (S25) or to a control group receiving a bolus of air. Within each group, animals were randomly assigned to either PPVCON, open lung PPV (PPVOLC), or open lung high-frequency oscillatory ventilation (HFOVOLC) and ventilated for 5 hrs.
MEASUREMENTS AND MAIN RESULTS: The ventilation pressures decreased in a dose-dependent way, showing the largest reduction in the S100 group. In both OLC groups, oxygenation, lung mechanics, and polymorphonuclear neutrophils analyzed in bronchoalveolar lavage were independent of the surfactant dose. In the PPVCON group, however, there was a clear dose-dependency, resulting in a deterioration of oxygenation and lung mechanics and an increase in polymorphonuclear neutrophils as the surfactant dose decreased. Although comparable between the three ventilation groups, bronchoalveolar lavage interleukin-8 concentrations significantly increased in all ventilation groups as the surfactant dose increased. Alveolar protein influx and conversion of large to small aggregate surfactant were higher during PPVCON compared with both OLC groups. There were no differences in the surfactant treatment response between PPVOLC and HFOVOLC.
CONCLUSION: Exogenous surfactant enables a reduction in ventilation pressures. Compared with PPVCON, the efficacy of surfactant treatment is less dose-dependent during open lung ventilation. Surfactant conversion during open lung ventilation is reduced compared with PPVCON. Exogenous surfactant seems to up-regulate bronchoalveolar lavage interleukin-8 concentrations, independent of the ventilation strategy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090961     DOI: 10.1097/01.ccm.0000114578.48244.21

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  Surfactant use based on the oxygenation response to lung recruitment during HFOV in VLBW infants.

Authors:  Pierre Tissières; Patrick Myers; Maurice Beghetti; Michel Berner; Peter C Rimensberger
Journal:  Intensive Care Med       Date:  2010-03-16       Impact factor: 17.440

2.  Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS.

Authors:  Marla R Wolfson; Jichuan Wu; Terrence L Hubert; Timothy J Gregory; Jan Mazela; Thomas H Shaffer
Journal:  Pediatr Res       Date:  2012-07-20       Impact factor: 3.756

3.  The effect of exogenous surfactant in patients with lung contusions and acute lung injury.

Authors:  I Tsangaris; E Galiatsou; E Kostanti; G Nakos
Journal:  Intensive Care Med       Date:  2007-03-22       Impact factor: 17.440

Review 4.  Bench-to-bedside review: Ventilator strategies to reduce lung injury -- lessons from pediatric and neonatal intensive care.

Authors:  Sally H Vitali; John H Arnold
Journal:  Crit Care       Date:  2004-11-04       Impact factor: 9.097

5.  Efficacy of a new technique - INtubate-RECruit-SURfactant-Extubate - "IN-REC-SUR-E" - in preterm neonates with respiratory distress syndrome: study protocol for a randomized controlled trial.

Authors:  Giovanni Vento; Roberta Pastorino; Luca Boni; Francesco Cota; Virgilio Carnielli; Filip Cools; Carlo Dani; Fabio Mosca; Jane Pillow; Graeme Polglase; Paolo Tagliabue; Anton H van Kaam; Maria Luisa Ventura; Milena Tana; Chiara Tirone; Claudia Aurilia; Alessandra Lio; Cinzia Ricci; Alessandro Gambacorta; Chiara Consigli; Danila D'Onofrio; Camilla Gizzi; Luca Massenzi; Viviana Cardilli; Alessandra Casati; Roberto Bottino; Federica Pontiggia; Elena Ciarmoli; Stefano Martinelli; Laura Ilardi; Mariarosa Colnaghi; Piero Giuseppe Matassa; Valentina Vendettuoli; Paolo Villani; Francesca Fusco; Diego Gazzolo; Alberto Ricotti; Federica Ferrero; Ilaria Stasi; Rosario Magaldi; Gianfranco Maffei; Giuseppe Presta; Roberto Perniola; Francesco Messina; Giovanna Montesano; Chiara Poggi; Lucio Giordano; Enza Roma; Carolina Grassia; Gaetano Ausanio; Fabrizio Sandri; Giovanna Mescoli; Francesco Giura; Giampaolo Garani; Agostina Solinas; Maria Lucente; Gabriella Nigro; Antonello Del Vecchio; Flavia Petrillo; Luigi Orfeo; Lidia Grappone; Lorenzo Quartulli; Antonio Scorrano; Hubert Messner; Alex Staffler; Giancarlo Gargano; Eleonora Balestri; Stefano Nobile; Caterina Cacace; Valerio Meli; Sara Dallaglio; Betta Pasqua; Loretta Mattia; Eloisa Gitto; Marcello Vitaliti; Maria Paola Re; Stefania Vedovato; Alessandra Grison; Alberto Berardi; Francesco Torcetta; Isotta Guidotti; Sandra di Fabio; Eugenia Maranella; Isabella Mondello; Stefano Visentin; Francesca Tormena
Journal:  Trials       Date:  2016-08-18       Impact factor: 2.279

Review 6.  Surfactant replacement therapy: from biological basis to current clinical practice.

Authors:  Roland Hentschel; Kajsa Bohlin; Anton van Kaam; Hans Fuchs; Olivier Danhaive
Journal:  Pediatr Res       Date:  2020-01-11       Impact factor: 3.756

7.  Surfactant replacement and open lung concept--comparison of two treatment strategies in an experimental model of neonatal ARDS.

Authors:  Anne Hilgendorff; Ece Aslan; Thomas Schaible; Ludwig Gortner; Thorsten Baehner; Michael Ebsen; Jochen Kreuder; Clemens Ruppert; Andreas Guenther; Irwin Reiss
Journal:  BMC Pulm Med       Date:  2008-07-14       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.